Novus Pharmaceuticals
Novus Pharmaceuticals, a leading name in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 2010, the company has made significant strides in developing innovative therapies, particularly in the fields of oncology and neurology. With a focus on delivering high-quality, patient-centric solutions, Novus Pharmaceuticals offers a range of unique products that address unmet medical needs. Their commitment to research and development has positioned them as a key player in the market, recognised for their contributions to advancing healthcare. Notable achievements include successful collaborations and a growing portfolio of proprietary medications, which underscore their dedication to improving patient outcomes. As Novus Pharmaceuticals continues to expand its global footprint, it remains at the forefront of pharmaceutical innovation.
DitchCarbon Score
How does Novus Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Furniture Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novus Pharmaceuticals's score of 15 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novus Pharmaceuticals's reported carbon emissions
In 2019, Novus Pharmaceuticals reported total carbon emissions of approximately 14,996,700 kg CO2e, which includes 4,609,750 kg CO2e from Scope 1 emissions and 10,386,950 kg CO2e from Scope 2 emissions. The company has not disclosed any specific reduction targets or initiatives as part of its climate commitments. Without defined reduction strategies or pledges, Novus Pharmaceuticals currently lacks a structured approach to mitigate its carbon footprint. The absence of significant climate commitments places the company in a challenging position within the industry, where many peers are actively pursuing ambitious sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novus Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
